Thomas Pike - 10 Jan 2025 Form 4 Insider Report for Fortrea Holdings Inc. (FTRE)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
14 Jan 2025, 18:08:57 UTC
Prior SEC filing
03 Dec 2024
Next SEC filing
03 Mar 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ James Stillman Hanson, Attorney-in-Fact for Thomas Pike

Key filing fact

Thomas Pike filed Form 4 for Fortrea Holdings Inc. (FTRE) on 14 Jan 2025.

Key facts

  • This page summarizes Thomas Pike's Form 4 filing for Fortrea Holdings Inc. (FTRE).
  • 3 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 14 Jan 2025, 18:08.

Change

  • Previous filing in this sequence was filed on 03 Dec 2024.
  • Current net transaction value: -$203,275.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

FTRE transaction

Common Stock

Options Exercise

Transaction value
$0
Shares
+40,220
Change %
+31%
Price
$0.000000
Shares after
171,136
Date
10 Jan 2025
Ownership
Direct
Footnotes
F1
FTRE transaction

Common Stock

Sale

Transaction value
$203,275
Shares
-11,268
Change %
-6.6%
Price
$18.04
Shares after
159,868
Date
13 Jan 2025
Ownership
Direct
Footnotes
F2, F3, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

FTRE transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value
$0
Shares
-40,220
Change %
-12%
Price
$0.000000
Shares after
291,611
Date
10 Jan 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
40,220
Exercise price
Footnotes
F1, F5, F6
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Each Restricted Stock Unit ("RSU") represents the contingent right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") Common Stock. This transaction represents the settlement of RSUs into Common Stock on their scheduled vesting date.

Footnote F2

The sales reported on this Form 4 represent shares of Common Stock sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

Footnote F3

This transaction was executed in multiple trades at prices ranging from $17.73 to $18.33. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Footnote F4

This number reflects the aggregate amount of Common Stock held by the reporting person.

Footnote F5

In connection with the spin-off of Fortrea by Laboratory Corporation of America Holdings ("Labcorp"), RSUs granted by Labcorp were converted into time-vesting RSUs of Fortrea pursuant to the terms of the Employee Matters Agreement. The second installment of the RSUs vested on January 10, 2025, and the third and final installment will vest on the third anniversary of Mr. Pike's original hiring date.

Footnote F6

This number reflects the aggregate number of RSUs held by the reporting person.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .